PAPD5 inhibitors and methods of use thereof
The PAPD5 inhibitor modulates TERC and telomerase activities, and solves the problem of difficult treatment of diseases caused by short telomeres in the prior art, and achieves the recovery of telomeres length and the improvement of related diseases.
CN119798159APending Publication Date: 2025-04-11CHILDRENS MEDICAL CENT CORP
5 Cites 0 Cited by
Patent Information
- Application Number
- CN202411839234.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-23
- Filing Date
- 2020-04-23
- Publication Date
- 2025-04-11
AI Technical Summary
Technical Problem
The prior art is difficult to effectively treat diseases caused by short telomeres, such as aplastic anemia, pulmonary fibrosis, cirrhosis and bone marrow failure, and there is a lack of effective medical treatments.
Method used
Provides PAPD5 inhibitors to restore TERC and telomerase function in cells of PARN mutant patients by regulating TERC levels and telomerase activity.
Benefits of technology
By using PAPD5 inhibitors, TERC levels and telomerase activity can be restored, thereby prolonging telomere length and improving the clinical manifestations of related diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are compounds that are PAPD5 inhibitors and are useful in the treatment of a variety of conditions, such as cancer, telomere disease, and aging-related disorders, as well as other degenerative disorders.
Need to check novelty before this filing date? Find Prior Art